Clinical trials: Cancer, Metastatic
Gastric Cancer, Gastroesophageal Junction Cancer
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
The main purpose of this study is to compare how long patients with gastric or gastroesophageal junction cancer live after receiving nivolumab and ipilimumab or nivolumab and chemotherapy compared with patients receiving…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Trial name
- CheckMate649 (NCT02872116)
- Testing
- Nivolumab, Ipilimumab, Oxaliplatin
- Where
- 179 sites in United States, Argentina and 27 more
- Volunteers
- 2,031 people
- Sponsor
- Bristol-Myers Squibb
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00453206
- Testing
- allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Wake Forest University Health Sciences
Liver Cancer, Metastatic Cancer
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor.
- Trial name
- NCT00003907
- Testing
- cisplatin, doxorubicin, mitomycin
- Where
- 37 sites in United States
- Volunteers
- 50 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)
Some human epidermal growth factor receptor 2 (HER-2) breast cancer patients do not respond or become resistant to current treatment. DS-8201a is a new experimental product that is a combination of an antibody and a drug.
- Trial name
- NCT03248492
- Testing
- DS-8201a
- Where
- 99 sites in United States, Belgium and 7 more
- Volunteers
- 253 people
- Sponsor
- Daiichi Sankyo
Carcinoma, Non-Small-Cell Lung
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with…
- Trial name
- PAPILLON (NCT04538664)
- Testing
- Amivantamab, Pemetrexed, Carboplatin
- Where
- 232 sites in United States, Australia and 24 more
- Volunteers
- 308 people
- Sponsor
- Janssen Research & Development, LLC
Colorectal Cancer
Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- PIMABI (NCT00655499)
- Testing
- Panitumumab, Irinotecan hydrochloride, Chromogenic in situ hybridization
- Where
- 9 sites in France
- Volunteers
- 65 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Prostate Cancer
Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer
Background: Flutamide is an approved drug for prostate cancer that blocks the effects of testosterone on prostate cancer cells and may slow the progression of the disease.
- Trial name
- NCT00450463
- Testing
- Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer, MSS
Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
This is a monocentric, single arm, prospective, open-label trial of a combination treatment consisting of pembrolizumab and maraviroc in previously treated subjects who have refractory microsatellite stable (MSS) metastatic…
- Trial name
- PICCASSO (NCT03274804)
- Testing
- Pembrolizumab, Maraviroc
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Head and Neck Cancer
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with recurrent or metastatic head and neck cancer.
- Trial name
- NCT00122460
- Testing
- Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU), Platinum (Cisplatin or Carboplatin) + 5-FU
- Where
- 70 sites in Austria, Belgium and 15 more
- Volunteers
- 442 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Prostate Cancer, Non-metastatic Prostate Cancer
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
This research study is trying to determine the safety and efficacy of the combination of two oral drugs, abemaciclib and darolutamide, with androgen deprivation therapy (ADT) in the treatment of metastatic, non-metastatic, and…
- Conditions
- Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer
- Trial name
- NCT05617885
- Testing
- Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Praful Ravi, MB BCHir, MRCP
Colorectal Cancer
Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer
A prospective, multi-center, phase II study of 21 patients to evaluate the efficacy of the epidermal growth factor receptor (EGFR) inhibitor, Cetuximab in patients with metastatic colorectal cancer (mCRC) harboring Adenomatous…
- Trial name
- APK Mutant (NCT04853043)
- Testing
- Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Utah
Solid Tumor Malignancy
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR…
- Trial name
- NCT03822117
- Testing
- Pemigatinib
- Where
- 90 sites in United States, Denmark and 9 more
- Volunteers
- 111 people
- Sponsor
- Incyte Corporation
Prostate Cancer
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.
- Trial name
- NCT00089674
- Testing
- AMG 162
- Volunteers
- 1,468 people
- Sponsor
- Amgen
Prostate Cancer
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients
The purpose of this study is to determine if continued treatment with Enzalutamide is effective in patients with metastatic prostate cancer.
- Trial name
- PLATO (NCT01995513)
- Testing
- Enzalutamide, Abiraterone, Prednisone
- Where
- 95 sites in United States, Australia and 9 more
- Volunteers
- 509 people
- Sponsor
- Pfizer
Lymphoma, Carcinoma
Continuous Infusion of rhIL-15 for Adults With Advanced Cancer
Background: People with cancer can have a weak immune system as a result of the cancer itself, or from prior treatments. Still, treatments that stimulate the immune system have been shown to be effective against a number of…
- Trial name
- NCT01572493
- Testing
- rh IL-15 (10 DAYS), rh IL-15 (5 DAYS)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Metastatic Cancer
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
This is an open-label, single-center, single-arm phase II clinical trial evaluating the combination of pembrolizumab, binimetinib, and bevacizumab in patients with metastatic colorectal adenocarcinoma who have not responded to…
- Trial name
- NCT03475004
- Testing
- Pembrolizumab, Bevacizumab, Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Colorado, Denver
Metastatic Renal Cell Carcinoma
Phase II Study of Alternating Sunitinib and Temsirolimus
In the past 5 years, treatment for metastatic Renal Cell Carcinoma (mRCC) has focused on agents directed at blocking tumor and vascular growth pathways.
- Trial name
- NCT01517243
- Testing
- Sunitinib, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck
This study will examine the effects of an investigational drug called AT-101 in combination with an FDA approved cancer drug called Docetaxel.
- Trial name
- NCT01285635
- Testing
- AT-101, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Michigan Rogel Cancer Center
IDH1-mutant Cholangiocarcinoma
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
This is a Phase 1/2 study evaluating the safety, tolerability, and activity of ivosidenib in combination with immunotherapy in participants with nonresectable or metastatic cholangiocarcinoma.
- Trial name
- NCT05921760
- Testing
- Ivosidenib, Nivolumab, Ipilimumab
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 7 people
- Sponsor
- Servier Bio-Innovation LLC
Non-Squamous Non-Small Cell Lung Cancer
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer.
- Trial name
- NCT00961415
- Testing
- bevacizumab [Avastin], cisplatin, pemetrexed
- Where
- 91 sites in France, Germany and 10 more
- Volunteers
- 376 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.